ACC Late-Breaking Clinical Trial sessions preview for day 1

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment with Alirocumab trial looks at similar outcomes but in a post–acute coronary syndrome population.

The data, to be presented by Philippe Gabriel Steg, MD, a professor of cardiology at the National Heart & Lung Institute at Imperial College, London, will change practice and potentially change guidelines, as it builds on the FOURIER results.

“How it influences our practices and how it affects guidelines will depend on the data presented, and the strength of the data will really help us decide just where it fits in to clinical practice,” said Dr. Kates, a professor of medicine and the director of the cardiology fellowship program at Washington University in St. Louis.